Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.

ABSTRACT:

Background

Single-gene tests and hotspot panels targeting specific subsets of biomarkers constitute the Canadian genomic testing landscape for non-small-cell lung cancer (nsclc). However, newer testing options such as comprehensive genomic profiling (cgp) offer improved detection rates and identification of multiple classes of genomic alterations in a single assay, minimizing tissue requirements and turnaround time. The objective of the present analysis was to assess the health and budget impacts of adopting cgp testing for nsclc in Canada.

Methods

This study assessed the impact of funding the cgp tests FoundationOne CDx and FoundationOne Liquid (Foundation Medicine, Cambridge, MA, U.S.A.) over a 3-year time horizon using a Canadian societal perspective for Ontario. Conventi

SUBMITTER: Johnston KM 

PROVIDER: S-EPMC7755443 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature